Patent Watch: Dey, L.P. v. Sunovion Pharms., Inc.
"[A]n agreement of confidentiality, or circumstances creating a similar expectation of secrecy, may negate a 'public use' where there is not commercial exploitation" [even] when an unaffiliated third party is responsible for the allegedly public use.
Pearl Therapeutics Initiates PT003 Phase 3 Program for the Treatment...
Pearl Therapeutics Inc. today announced the initiation of PINNACLE, a global Phase 3 program of PT003 , the Company's fixed-dose combination of glycopyrrolate, a long-acting muscarinic antagonist and formoterol fumarate, a long-acting beta-2 agonist , delivered via a pressurized hydrofluoroalkane using the Company's novel co-suspension formulation ... (more)
Assessing Your Asthma is Key to Taking Control
Approximately 25 million Americans suffer from asthma, which accounts for more than 3300 deaths each year.
Second Phase III Study For Aclidinium And Formoterol Combination In COPD Produces Positive Results
Aclidinium/formoterol demonstrates consistent, statistically significant lung function improvement in the second pivotal efficacy trial.
Positive Phase III Results With Aclidinium/Formoterol in COPD
Positive results have been reported from the AUGMENT/COPD trial, the second 6-month pivotal phase III study of investigational fixed-dose combinations of aclidinium bromide and formoterol fumarate , delivered in the Pressair inhaler.
Customer Interaction Solutions
Forest Laboratories and Almirall Announce Positive Results for the...
Forest Laboratories, Inc. and Almirall, S.A. today announced positive topline results from AUGMENT COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide and formoterol fumarate , delivered in the Pressair inhaler.